2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Surgical, Workforce, Adverse Events, Artificial Intelligence (AI), Generative AI, Natural Language Processing, Biological Processes, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Telemedicine, Value, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

6177 Antihypertensives’ effect on incidence and severity of cytokine release syndrome with bi-specific therapies

Michelle Nguyen, PharmD, Gloria Espinosa, PharmD2, Jennifer Rauscher, MSN3, Katelyn Clancy4, Adam Binder, MD5
1 Thomas Jefferson University Hospital, Philadelphia, United States
2 Thomas Jefferson University Hospital, Philadelphia, United States
3 Thomas Jefferson University Hospital, Philadelphia, United States
4 Thomas Jefferson University Hospital, Philadelphia, United States
5 Thomas Jefferson University Hospital, Philadelphia, United States

Background   

Bispecific T-cell engagers (BiTEs) are a type of targeted immunotherapy that simultaneously bind to tumor-associated antigens on tumor cells and receptors on T-cells, activating an endogenous cytotoxic immune response. This immune activation can trigger cytokine release syndrome (CRS) and/or immune effector cell-associated neurotoxicity syndrome (ICANS). In particular, CRS is characterized by fever at onset and may include hypotension, capillary leak (hypoxia), and end organ dysfunction. This study focuses on mitigating CRS risk, specifically if holding patients' home antihypertensives (aHTN) can reduce the risk of hypotension associated with CRS, leading to improved quality of care and patient safety.   

Methods   

All patients who received at least one step-up dose of blinatumomab, epcoritamab, elranatamab, teclistamab, talquetamab, and/or glofitamab between November 1, 2024 and November 30, 2025 while admitted at TJUH were included in this retrospective cohort analysis. The primary outcome only included patients who were prescribed aHTN medications at the time of BiTE step-up dose per chart review. aHTNs included were: angiotensin-converting enzyme inhibitors, angiotension II receptor blockers, beta-blockers, calcium channel blockers, loop diuretics, neprilysin inhibitors, and vasodilators. The data points collected included BiTE received, whether a CRS event occurred, grade of CRS, and the lowest blood pressures recorded within 24 and 48 hours of a BiTE step-up dose. The primary outcome was incidence and grade of CRS within 48 hours following BiTE step-up dosing in which home aHTNs were held prior to BiTE dosing compared with when home aHTNs were not held. There were two secondary outcomes: 1) overall incidence and grade of CRS among all BiTE step-up dose administrations and 2) incidence and grade of CRS in all BiTE step-up dose administrations among patients who were on aHTNs at home compared with those who were not on any aHTNs at home.  

Results   

45 patients, median age 65 years (range 1-85), received at least one BiTE step-up dose. A total of 126 step-up doses were administered. For blinatumomab, each dose escalation or restart of the infusion >4 hours was considered one step up dose (ie: 9mg and 28mg). Teclistamab was the most common BiTE administered (46.7%).   

Of the 45 patients included in the study, 26 patients (57.8%) were prescribed an aHTN medication at home and included in our primary outcome. These 26 patients had a total of 78 BiTE step-up doses. The incidence of CRS was 30/78 (38.5%), which included 27 grade 1 events (90%), two grade 2 events (15%), and one grade 3 event (3.3%). Of the 78 BiTE step-up doses, home aHTNs were held prior to 14 of those doses and consisted of 6 CRS events (42.9%), all of which were grade 1 (100%). This is compared with 22 CRS events out of 59 (37.3%) BiTE step-up doses in which the home aHTNs were not held, of which 20 events were grade 1 (90.9%) and two were grade 2 (9.1%). The difference in incidence of CRS (42.9% versus 37.3%) was not statistically significant (χ2 = 0.15, p = 0.700). There were 5 BiTE step-up dose administrations where it was unable to be determined whether aHTNs were held or continued, and were excluded.  

For the secondary outcomes, all 48 patients and 128 BiTE step-up dose administrations were included. The overall incidence of CRS was 40 events (31.7%). When comparing patients on an aHTN at home versus patients not on any aHTNs at home, the incidences of CRS were 38.5% (30/78) and 20.8% (10/48), respectively (χ2 = 4.26, p = 0.039). More patients who were on aHTNs at home had grade 2 or more CRS events (10% versus 0%).   

Conclusions  

These findings suggest that holding patients' home antihypertensives prior to administering a step-up dose of a BITE may reduce the risk of grade 2 CRS. While our study did not reach significance to determine holding of aHTN medications prior to treatment, we did find patients prescribed these medications at baseline have a higher risk of CRS. Limitations include small sample size and retrospective design. Providers should assess all patients initiating step-up dosing for clinical ability to tolerate time off antihypertensives during timing at highest risk for CRS, though further studies are needed to prospectively evaluate this measure as a CRS mitigation strategy. 

Michelle Nguyen, PharmD: No relevant conflicts of interest to declare.